發(fā)布時(shí)間：2018-10-18 17:56

【摘要】：目的:通過對現(xiàn)有micro RNA-210在肺癌中診斷價(jià)值的研究進(jìn)行系統(tǒng)綜述和薈萃分析,探討micro RNA-210對肺癌的診斷價(jià)值。方法:在Pubmed、Embase、Web of Knowledge、Cochrane Library、CNKI、維普和萬方數(shù)據(jù)庫中全面檢索文獻(xiàn),按照納入及排除標(biāo)準(zhǔn)篩選出合格文獻(xiàn),根據(jù)QUADAS-2評價(jià)文獻(xiàn)質(zhì)量并提取所需數(shù)據(jù),使用Stata 12.0和Meta-disc 1.4進(jìn)行統(tǒng)計(jì)分析,應(yīng)用雙變量隨機(jī)混合效應(yīng)模型得出合并診斷值,并進(jìn)一步應(yīng)用層次綜合受試者工作特征曲線(HSROC)驗(yàn)證上述結(jié)果。此外,評估各研究間異質(zhì)性和發(fā)表偏倚。結(jié)果:本項(xiàng)meta分析最終納入9篇文獻(xiàn),共包括993例樣本(554例肺癌患者和439例非肺癌對照)。應(yīng)用雙變量隨機(jī)混合效應(yīng)模型經(jīng)統(tǒng)計(jì)分析得出,micro RNA-210對肺癌診斷的合并靈敏度、特異度、陽性似然比、陰性似然比及診斷比值比分別為0.66(95%CI:0.57~0.75),0.82(95%CI:0.72~0.89),3.64(95%CI:2.54~5.21),0.41(95%CI:0.34~0.51),8.78(95%CI:6.10~12.66)。擬合受試者工作曲線的曲線下面積為0.80(95%CI:0.76~0.83)。此外,HSROC曲線顯示SROC曲線對稱,?值為2.08(95%CI:1.76~2.40),HSROC模型同樣表明micro RNA-210在肺癌中診斷價(jià)值中等。由于各文獻(xiàn)間存在異質(zhì)性,進(jìn)行meta回歸分析和亞組分析探索可能的異質(zhì)性來源,結(jié)果顯示,國家、腫瘤分期、肺癌類型、樣本種類和內(nèi)參等變量均不是異質(zhì)性來源。Deeks’漏斗圖顯示各研究無發(fā)表偏倚,Spearman等級相關(guān)檢驗(yàn)顯示不存在閾值效應(yīng)。結(jié)論:Micro RNA-210在肺癌中診斷價(jià)值中等,仍需更多前瞻性研究進(jìn)一步證實(shí)micro RNA-210在肺癌中的診斷價(jià)值。
[Abstract]:Objective: to study the diagnostic value of micro RNA-210 in lung cancer by systematic review and meta-analysis. Methods: the literature was searched in the database of Pubmed,Embase,Web of Knowledge,Cochrane Library,CNKI, Weip and Wanfang, and qualified literature was screened according to the inclusion and exclusion criteria. The quality of literature was evaluated according to QUADAS-2 and the required data were extracted. Stata 12.0 and Meta-disc 1.4 were used for statistical analysis. The combined diagnostic value was obtained by using the two-variable random mixing effect model, and the above results were verified by the hierarchical synthetic operating characteristic curve (HSROC). In addition, heterogeneity and publication bias among studies were assessed. Results: this meta analysis included 9 articles, including 993 samples (554 lung cancer patients and 439 non-lung cancer controls). The combined sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic ratio of micro RNA-210 for lung cancer were 0.66 (95%CI:0.57~0.75), 0.82 (95%CI:0.72~0.89), 3.64 (95%CI:2.54~5.21), 0.41 (95%CI:0.34~0.51), 8.78 (95%CI:6.10~12.66), respectively. The area under the curve fitted to the operating curve was 0. 80 (95%CI:0.76~0.83). In addition, the HSROC curve shows the symmetry of the SROC curve,? The value of micro RNA-210 was 2.08 (95%CI:1.76~2.40), HSROC model also showed that micro RNA-210 was of moderate value in the diagnosis of lung cancer. Due to the heterogeneity in various literatures, meta regression analysis and subgroup analysis were carried out to explore the possible sources of heterogeneity. The results showed that country, tumor stage, lung cancer type, Deeks' funnel graph showed that there was no publication bias in each study, and Spearman grade correlation test showed that there was no threshold effect. Conclusion: the diagnostic value of Micro RNA-210 in lung cancer is moderate, and more prospective studies are needed to further confirm the diagnostic value of micro RNA-210 in lung cancer.
【學(xué)位授予單位】：首都醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R734.2
，

本文編號(hào)：2279920